Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Jul 10, 2021 10:08am
597 Views
Post# 33526482

Shares Owed For Debt !!!

Shares Owed For Debt !!!I see a friend of a friend losing their sh.t on another board ..but they do have valid questions which can be answered ..yet still with a pause ... ..not sure if anyone realizes that stockwatch has some xtra nr compared to sedar ... 4/15 and 06/07 nr are re shares for debt which has been cleared by the sec and Claritas will advise when they will be issued in a nr....6.8m and 700k approx if I remember correctly....these shares along with shares to Salzman I think they are waiting to do the rs then announce... due to this long dragged out process has faithful investors losing interest and questioning the expertise of mgmt and the company's past history ....I think they are waiting to get tax rebate in house...lisence for Pah and firm start date of clinical trial ..rs complete....along with hopefully more such as a new drug authorization and govt FDA or UK pass ....all in hopes to announce together to run the sp up ....so for me I will hope that starting this week we will see something in place to stay on track with clinical trials to be completed b4 yr end ....if not I will piggyback on my new best friends with upset....but due to this long process I keep hoping there's a relationship happening .... this is imo...glta
<< Previous
Bullboard Posts
Next >>